Literature DB >> 1452712

An enzyme-linked immunosorbent assay for enumeration of Pneumocystis carinii in vitro and in vivo.

M M Durkin1, M S Bartlett, S F Queener, M M Shaw, C H Lee, J W Smith.   

Abstract

An enzyme-linked immunosorbent assay (ELISA) to quantitate Pneumocystis carinii organisms from culture supernatant and rat lung has been developed. A polyclonal antibody specific to P. carinii was produced in Sprague-Dawley rats by allowing P. carinii-infected animals to recover from infection. This antibody reacted strongly to P. carinii proteins of 50 to 55 kDa and weakly to those of 33 and 116 kDa. The ELISA used this convalescent-phase antibody to quantitate the number of P. carinii organisms in lung homogenates of infected rats and supernatants from infected tissue cultures which were used to screen drugs for P. carinii. The results of the ELISA were compared with those of direct microscopic counting of organisms, and the two methods were highly correlated (r > 0.9). Thus, the ELISA can be used as an alternative method for the quantitation of P. carinii organisms, and it is superior to the conventional microscopic method because it is easier to perform and less labor-intensive.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1452712      PMCID: PMC270644          DOI: 10.1128/jcm.30.12.3258-3262.1992

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  14 in total

1.  A NEW PROCEDURE FOR THE IDENTIFICATION OF PNEUMOCYSTIS CARINII CYSTS IN TISSUE SECTIONS AND SMEARS.

Authors:  A M CHALVARDJIAN; L A GRAWE
Journal:  J Clin Pathol       Date:  1963-07       Impact factor: 3.411

2.  An improved rat model to study efficacy of drugs for treatment or prophylaxis of Pneumocystis carinii pneumonia.

Authors:  M S Barlett; J A Fishman; M M Durkin; S F Queener; J W Smith
Journal:  J Protozool       Date:  1989 Jan-Feb

3.  Activity of lipid-soluble inhibitors of dihydrofolate reductase against Pneumocystis carinii in culture and in a rat model of infection.

Authors:  S F Queener; M S Bartlett; M A Jay; M M Durkin; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

4.  Antimicrobial susceptibility of Pneumocystis carinii in culture.

Authors:  M S Bartlett; R Eichholtz; J W Smith
Journal:  Diagn Microbiol Infect Dis       Date:  1985-09       Impact factor: 2.803

5.  Ten-minute silver stain for Pneumocystis carinii and fungi in tissue sections.

Authors:  L Musto; M Flanigan; A Elbadawi
Journal:  Arch Pathol Lab Med       Date:  1982-06       Impact factor: 5.534

6.  Pneumocystis carinii pneumonitis in patients with lung cancer.

Authors:  B E Fossieck; S V Spagnolo
Journal:  Chest       Date:  1980-11       Impact factor: 9.410

7.  Serologic methods for the early diagnosis of Pneumocystis carinii infection in renal allograft recipients.

Authors:  M Jarowenko; L Pifer; R Kerman; B D Kahan
Journal:  Transplantation       Date:  1986-04       Impact factor: 4.939

8.  Survival with the acquired immunodeficiency syndrome. Experience with 5833 cases in New York City.

Authors:  R Rothenberg; M Woelfel; R Stoneburner; J Milberg; R Parker; B Truman
Journal:  N Engl J Med       Date:  1987-11-19       Impact factor: 91.245

9.  Pneumocystis carinii pneumonia therapy with 9-deazainosine in rats.

Authors:  J W Smith; M S Bartlett; S F Queener; M M Durkin; M A Jay; M T Hull; R S Klein; J J Marr
Journal:  Diagn Microbiol Infect Dis       Date:  1987-06       Impact factor: 2.803

10.  Efficacy of trimethoprim and sulfamethoxazole in the prevention and treatment of Pneumocystis carinii pneumonitis.

Authors:  W T Hughes; P C McNabb; T D Makres; S Feldman
Journal:  Antimicrob Agents Chemother       Date:  1974-03       Impact factor: 5.191

View more
  9 in total

1.  A novel approach to restore lung immunity during systemic immunosuppression.

Authors:  William J Martin; Min Wu; Rajamouli Pasula
Journal:  Trans Am Clin Climatol Assoc       Date:  2005

2.  Antibody to Pneumocystis carinii protects rats and mice from developing pneumonia.

Authors:  M S Bartlett; W C Angus; M M Shaw; P J Durant; C H Lee; J M Pascale; J W Smith
Journal:  Clin Diagn Lab Immunol       Date:  1998-01

3.  Close association of Pneumocystis carinii from infected rat lung with culture cells as shown by light and electron microscopy.

Authors:  M S Bartlett; M P Goheen; C H Lee; M M Shaw; M M Durkin; J W Smith
Journal:  Parasitol Res       Date:  1994       Impact factor: 2.289

4.  Use of semiquantitative PCR to assess onset and treatment of Pneumocystis carinii infection in rat model.

Authors:  T J O'Leary; M M Tsai; C F Wright; M T Cushion
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

5.  Identification of a class of sulfonamides highly active against dihydropteroate synthase form Toxoplasma gondii, Pneumocystis carinii, and Mycobacterium avium.

Authors:  L C Chio; L A Bolyard; M Nasr; S F Queener
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

6.  Evaluation of potent inhibitors of dihydrofolate reductase in a culture model for growth of Pneumocystis carinii.

Authors:  M S Bartlett; M Shaw; P Navaran; J W Smith; S F Queener
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

7.  8-aminoquinolines effective against Pneumocystis carinii in vitro and in vivo.

Authors:  S F Queener; M S Bartlett; M Nasr; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

8.  Proliferation of rat Pneumocystis carinii on cells sheeted on microcarrier beads in spinner flasks.

Authors:  C H Lee; N L Bauer; M M Shaw; M M Durkin; M S Bartlett; S F Queener; J W Smith
Journal:  J Clin Microbiol       Date:  1993-06       Impact factor: 5.948

9.  Albendazole inhibits Pneumocystis carinii proliferation in inoculated immunosuppressed mice.

Authors:  M S Bartlett; T D Edlind; C H Lee; R Dean; S F Queener; M M Shaw; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1994-08       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.